NKA Bio is developing therapeutic antibodies
to buy more time for life-saving care

About

About NKA Bio

Who:

NKA Bio is developing new medicines to improve critical care. Our lead product is NKA01, a temperature-stable antibody for trauma patients.

Problem:

When you are severely injured, it is a race against time to get to surgery. The average person dies 8 minutes before lifesaving treatment can be delivered.

Solution:

But in the future, when minutes count, our antibody will buy hours. At NKA Bio, our treatment presses pause on death. With an injection of NKA01 by EMS, our drug could buy more time for transport and lifesaving surgery.

The Problem

Problem

When you are severely injured, it is a race against time to get to surgery, because the average person dies 8 minutes before lifesaving treatment can be delivered.

In Addition to the 90,000 trauma patients who don't live long enough to get to a hospital... Every year:

990,000

Patients Transported by Ambulance to Trauma Centers

210,000

So Injured they Require ICU Care to be Stabilized

44,000

Die at Trauma Centers Despite Recieving the Best Care

Our Solution

Solution

Introducing NKA01

When minutes count, our antibody buys hours. NKA01 presses pause on death with a low-volume injection at the point of injury to buy more time for transport and lifesaving surgery.

Product:

Prefilled Syringe with our Anti-Shock Toxin Antibody for Injection by EMS during their standard treatment protocols to prepare the patient for transport.

Key Features:

Temperature stable and low volume for field use by EMS to immediately stabilize trauma patients and press pause on death to buy more time for transport to a trauma center for care.

Progress to Date:

Proof of Concept In Vivo with a Prototype. Lead Candidate Selected.

Pipeline

Critical Care Focused

World Health Organization

Team

Gann Headshop Hopkins Surgery_edited.jpg

Shock Pioneer Behind Discovery

(1932 - 2020)

Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's research was continuously funded by the NIH to study the body's response to hemorrhage.